Janney Montgomery Scott LLC Cuts Stake in Medtronic PLC $MDT

Janney Montgomery Scott LLC lessened its stake in shares of Medtronic PLC (NYSE:MDT) by 16.2% during the second quarter, HoldingsChannel reports. The firm owned 1,195,485 shares of the medical technology company’s stock after selling 231,677 shares during the period. Janney Montgomery Scott LLC’s holdings in Medtronic were worth $93,523,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of MDT. Mccarter Private Wealth Services LLC grew its stake in shares of Medtronic by 31.5% in the second quarter. Mccarter Private Wealth Services LLC now owns 5,132 shares of the medical technology company’s stock valued at $401,000 after buying an additional 1,229 shares in the last quarter. North Dakota State Investment Board lifted its position in Medtronic by 2.6% during the 2nd quarter. North Dakota State Investment Board now owns 38,133 shares of the medical technology company’s stock worth $2,983,000 after acquiring an additional 983 shares in the last quarter. USA Financial Formulas boosted its holdings in Medtronic by 6.5% in the 1st quarter. USA Financial Formulas now owns 3,193 shares of the medical technology company’s stock worth $277,000 after acquiring an additional 196 shares during the period. Midwest Trust Co boosted its holdings in Medtronic by 2.4% in the 2nd quarter. Midwest Trust Co now owns 257,916 shares of the medical technology company’s stock worth $20,177,000 after acquiring an additional 6,071 shares during the period. Finally, R Squared Ltd grew its position in Medtronic by 79.1% in the second quarter. R Squared Ltd now owns 20,617 shares of the medical technology company’s stock valued at $1,613,000 after acquiring an additional 9,104 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic outperformed the broader market in the latest session, closing higher as investors focused on the company’s defensive medical-device exposure. Medtronic Advances While Market Declines
• Positive Sentiment: Seventeen analysts have issued targets over the past six months, with a median target of $101, implying additional upside from recent levels. Targets range widely, however, from $83 to $119. Medtronic Analyst Targets and Trading Data
• Neutral Sentiment: Value-focused coverage is comparing MDT with Agilent Technologies, indicating that investors are evaluating Medtronic’s valuation against peers rather than responding to a major new company-specific catalyst. MDT Versus Agilent for Value Investors
• Neutral Sentiment: Institutional positioning was mixed in the latest reported quarter: 998 investors increased holdings while 1,327 reduced positions, including sizable additions by JPMorgan and reductions by Capital Research and UBS. Medtronic Institutional Activity
• Negative Sentiment: Quiver estimated CEO Geoff Martha’s 2026 compensation at $22.9 million, up 7.4% year over year. It also reported eight open-market insider sales and no purchases over the past six months, which may raise governance and confidence concerns. Medtronic CEO Compensation and Insider Sales
• Negative Sentiment: BTIG reaffirmed a “buy” rating but set a $91 price target, below recent trading levels, signaling limited near-term upside in that analyst’s view. BTIG Reaffirms Medtronic Buy Rating

Insider Activity

In other news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $80.44, for a total transaction of $336,963.16. Following the transaction, the executive vice president owned 37,227 shares of the company’s stock, valued at approximately $2,994,539.88. This trade represents a 10.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.26% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on MDT. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Medtronic from $100.00 to $78.00 and set a “hold” rating on the stock in a research note on Thursday, June 4th. Wells Fargo & Company lowered their price target on shares of Medtronic from $114.00 to $102.00 and set an “overweight” rating for the company in a report on Thursday, June 4th. Sanford C. Bernstein cut their price objective on shares of Medtronic from $112.00 to $97.00 and set an “outperform” rating on the stock in a report on Thursday, June 4th. Truist Financial lowered their target price on Medtronic from $95.00 to $86.00 and set a “hold” rating for the company in a research note on Thursday, June 4th. Finally, Stifel Nicolaus set a $80.00 target price on Medtronic in a research report on Wednesday, June 3rd. Eighteen research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $98.83.

Medtronic Stock Up 1.8%

Shares of NYSE:MDT opened at $92.22 on Wednesday. The company has a current ratio of 2.13, a quick ratio of 1.62 and a debt-to-equity ratio of 0.52. The company has a fifty day simple moving average of $83.60 and a 200 day simple moving average of $86.13. The firm has a market cap of $118.04 billion, a PE ratio of 24.72, a price-to-earnings-growth ratio of 2.45 and a beta of 0.55. Medtronic PLC has a 12-month low of $73.31 and a 12-month high of $106.33.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.01. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The firm had revenue of $9.81 billion for the quarter, compared to analysts’ expectations of $9.62 billion. During the same period in the prior year, the company posted $1.62 earnings per share. The firm’s quarterly revenue was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, equities research analysts anticipate that Medtronic PLC will post 5.94 EPS for the current fiscal year.

Medtronic Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, July 17th. Stockholders of record on Friday, June 26th were paid a $0.72 dividend. This is a boost from Medtronic’s previous quarterly dividend of $0.71. The ex-dividend date was Friday, June 26th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.1%. Medtronic’s dividend payout ratio (DPR) is currently 77.21%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).